Featured Research

from universities, journals, and other organizations

Drug Combination May Slow Male Breast Cancer Growth

Date:
July 7, 2006
Source:
University of Cincinnati
Summary:
Medical oncologists want to know whether a new drug combination can slow the progression of male breast cancer, a rare disease that often goes undiagnosed until it's in an advanced stage. Zeina Nahleh, M.D., of the University of Cincinnati, is leading a national phase-2 clinical trial to test whether the drug anastrozole (Arimidex), currently approved by the FDA for treating breast cancer in postmenopausal women, can effectively fight the same disease in men.

Medical oncologists across the nation want to know whether a certain drug combination can slow the progression of male breast cancer, a rare disease that often goes undiagnosed until it’s in an advanced stage.

Related Articles


Zeina Nahleh, MD, director of breast oncology in the University of Cincinnati’s (UC) division of hematology and oncology, is leading a national phase-2 clinical trial to test whether the drug anastrozole (Arimidex), currently approved by the Food and Drug Administration (FDA) for treating breast cancer in postmenopausal women, can effectively fight the same disease in men.

“If we’re going to make significant advances against the disease,” says Nahleh, “we need better male-specific treatment strategies.”

Previous research has shown that the female hormone estrogen promotes the growth of certain types of breast cancer. Anastrozole is one of a class of drugs, known as non-steroidal aromatase inhibitors, that block the tumor’s use of estrogen and slow its development.

By treating male breast cancer with a combination of anastrozole and a synthetic hormone called goserelin, Nahleh believes physicians may be able to stop the transition of the male hormone testosterone to the estrogen estradiol, significantly lowering the man’s overall estrogen levels and limiting breast tumor growth.

Goserelin is what is known as a gonadotropin-releasing hormone, which stops testosterone production in men and decreases estradiol in women. It already has FDA approval for the treatment of prostate cancer, endometriosis and advanced premenopausal and perimenopausal breast cancer.

“The biology of breast cancer is different in men and women, so identical treatment methods are not the best solution,” explains Nahleh. “We believe that anastrozole—when used in conjunction with a gonadotropin-releasing hormone injection—will lower the amount of male estrogen in the body, resulting in better control of the breast tumor.”

The trial, sponsored by the National Cancer Institute and Southwest Oncology Group, is the first to test this specific drug combination in men with advanced breast cancer.

“We’ve seen a 26 percent increase in the number of male breast cancer cases since 1973, but the disease is so rare that there’s been little research to determine the best ways to detect and treat the disease specifically in men,” explains Nahleh.

Current male breast cancer treatment methods are based on accepted approaches to the disease in women. Unlike female breast cancer, says Nahleh, the relationship between the estrogen receptor and overall survival in men is uncertain. In addition, mortality from the disease has not declined as it has in women.

Under Nahleh’s direction, researchers from 53 medical centers nationwide will test the drug combination on about 60 male patients—age 18 or older—who have recurrent or advanced breast cancer.

Patients will receive an anastrozole pill every day and a goserelin injection on the first day of 12, month-long cycles. Every two months researchers will collect serum samples to evaluate blood estrogen levels. They will also obtain CAT scan and X-ray images of the tumor to determine how the patient is responding.

After the treatment, Nahleh and her team will follow patients for three years to determine whether the approach is a sustainable option for managing male breast cancer.

The American Cancer Society estimates that more than 1,700 men will be diagnosed with breast cancer in 2006 and about 27 percent will die from the disease.


Story Source:

The above story is based on materials provided by University of Cincinnati. Note: Materials may be edited for content and length.


Cite This Page:

University of Cincinnati. "Drug Combination May Slow Male Breast Cancer Growth." ScienceDaily. ScienceDaily, 7 July 2006. <www.sciencedaily.com/releases/2006/07/060707093951.htm>.
University of Cincinnati. (2006, July 7). Drug Combination May Slow Male Breast Cancer Growth. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2006/07/060707093951.htm
University of Cincinnati. "Drug Combination May Slow Male Breast Cancer Growth." ScienceDaily. www.sciencedaily.com/releases/2006/07/060707093951.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins